Document Detail

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
MedLine Citation:
PMID:  14595084     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). This study was conducted to examine dosage effects on ADHD symptoms and stimulant side effects and to explore potential moderating effects of ADHD subtype. METHODS: Children with ADHD combined type (ADHD-CT) or predominantly inattentive type (ADHD-PI; n = 47), ages 5 to 16 years, underwent a placebo-controlled, crossover trial using forced titration with weekly switches at 3 dosage levels. Parent and teacher ratings of ADHD symptoms were used to evaluate efficacy. In addition, vital signs and standardized measures of stimulant side effects were obtained weekly. RESULTS: Parent ratings were more sensitive to treatment effects than teacher ratings. ADHD symptoms and Clinical Global Impressions Severity Index ratings at each dose condition differed significantly from placebo and baseline ratings, which did not differ from one another. For those with ADHD-CT, there was a clear linear dose-response relationship, with clinically significant reductions in ADHD Rating Scale-IV scores occurring in two thirds to three fourths of the subjects during either 36- or 54-mg dose conditions. Children with ADHD-PI, conversely, were more likely to respond optimally to lower doses and derived less benefit from higher doses, with 60% displaying significant improvement on the ADHD Rating Scale-IV at 36 mg or lower. Mild stimulant side effects were reported during placebo and at all dosage levels. With the exception of insomnia and decreased appetite, which were more common at higher doses, parent report of side effects was not related to dose. In addition, younger and smaller children were more likely to display sleep difficulties and decreased appetite at the higher dose levels Although pulse rate increased slightly with increasing dose, there were no dose effects on blood pressure. CONCLUSIONS: In children with ADHD-CT, the most common subtype of ADHD, increasing doses of stimulant medication were associated with increased improvement of inattention and hyperactivity symptoms. In children with ADHD-PI, symptom improvement occurred at lower doses and less benefit was derived from higher doses. In both ADHD subtypes, higher doses were associated with parent ratings of increased insomnia and decreased appetite.
Mark A Stein; Christopher S Sarampote; Irwin D Waldman; Adelaide S Robb; Charles Conlon; Phillip L Pearl; David O Black; Karen E Seymour; Jeffrey H Newcorn
Related Documents :
23835384 - Evaluation of hybrid inverse planning and optimization (hipo) algorithm for optimizatio...
24694804 - Impact of microdose clinical trials in the preclinical stage.
8998124 - Low-dose recombinant human growth hormone increases body weight and lean body mass in p...
24996294 - Clinical implementation of the national electrical manufacturers association ct dose ch...
21131664 - An assessment of the external radiological impact in granites and pegmatite in central ...
20386884 - Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Pediatrics     Volume:  112     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-03     Completed Date:  2003-11-25     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e404     Citation Subset:  AIM; IM    
Department of Psychiatry, University of Chicago, Chicago, Illinois 60637, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Attention Deficit Disorder with Hyperactivity / drug therapy*
Central Nervous System Stimulants / administration & dosage,  adverse effects,  therapeutic use*
Child, Preschool
Cross-Over Studies
Delayed-Action Preparations
Dose-Response Relationship, Drug
Eating Disorders / chemically induced
Methylphenidate / administration & dosage,  adverse effects,  therapeutic use*
Parents / psychology
Patient Compliance
Severity of Illness Index
Sleep Initiation and Maintenance Disorders / chemically induced
Tics / chemically induced
Grant Support
Reg. No./Substance:
0/Central Nervous System Stimulants; 0/Delayed-Action Preparations; 113-45-1/Methylphenidate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Childhood cancer among Alaska Natives.
Next Document:  Low glycemic index breakfasts and reduced food intake in preadolescent children.